Arguing against this possibility, levels of E-Cadherin were not significantly increased between BPH compared to prostate carcinoma, or between matched tumour and normal prostate tissue from patients (Figure 2—figure supplement 1). Here, CDH1 is linked to benign prostatic hyperplasia.